Market Cap 8.17M
Revenue (ttm) 10,000.00
Net Income (ttm) -6.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60,000.00%
Debt to Equity Ratio 0.00
Volume 11,900
Avg Vol 56,102
Day's Range N/A - N/A
Shares Out 3.70M
Stochastic %K 50%
Beta 1.87
Analysts Sell
Price Target $20.00

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology
Sector: Healthcare
Phone: 480 399 2822
Address:
211 East Osborn Road, Phoenix, United States
Kjstock
Kjstock May. 15 at 12:09 AM
$CELZ I wish that this was us! https://scitechdaily.com/scientists-reverse-stroke-damage-using-stem-cells-in-breakthrough-study/
1 · Reply
jcooptechit
jcooptechit May. 14 at 7:01 PM
$CELZ MAY BE NEARING A MAJOR BIOTECH INFLECTION POINT Creative Medical Technology is heading into a key May 2026 catalyst with top-line Phase 2 data expected for CELZ-201-DDT in chronic low-back pain linked to DDD. 🔸 Phase 2 clinical readout pending 🔸 Chronic pain / DDD = massive market 🔸 Multiple active Phase 2 programs 🔸 DSMB previously supported trial continuation 🔸 No Phase 3 results yet, so this is still early — but high-impact Strong data could quickly change the CELZ narrative and bring serious attention back to its regenerative medicine platform. This next update could be the spark. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $ABEO $ALLO $AUTL $CARM
0 · Reply
JTE_Theta
JTE_Theta May. 14 at 5:38 PM
Everyone's chasing AI stocks. Meanwhile $CELZ is quietly running one of the most interesting clinical pipelines in small cap biotech. Creative Medical Technology Holdings, $8.5M market cap. And a pipeline that punches way above its weight. Here's the story 🧵 79% of back pain patients hit meaningful improvements in pain & function. DSMB cleared. Zero safety flags. Then April 2026 - Ultrasome drops a 93% response rate in knee OA. Cell-free. Scalable. Whole new market unlocked. WHO has assigned INNs to TWO separate programs. Rare for any micro cap. Topline ADAPT data + T1 Diabetes readout both expected NOW. $20 B+ spinal market. FDA Fast Track. 60+ patents. Trading at $2.20 The market hasn't priced this in yet ommunicated Disclaimer:http://tinyurl.com/bdduhp5k
0 · Reply
jcooptechit
jcooptechit May. 14 at 2:42 PM
$CELZ COULD BE ONE CATALYST AWAY FROM A MAJOR MOMENTUM RE-RATE Creative Medical is tightening right as CELZ-201-DDT Phase 2 results for chronic low-back pain are expected in May 2026. Key levels on watch: * Accumulation: $1.70–$1.82 * Reaccumulation: $2.02–$2.20 * Breakout: $2.32 * Major Resistance: $2.72 🎯 Target Zone: $3.31–$3.68 The roadmap is simple: hold $2.02–$2.20, reclaim $2.32, attack $2.72, then eyes on $3.31+ With Phase 2 results potentially due any day now, volume confirmation could turn this setup from quiet accumulation into a serious catalyst-driven move. Keep CELZ locked in. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $VTGN $LCTX $ATHX.X $PSTV
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb May. 14 at 12:38 AM
$CELZ will find out soon if we're going to Phase 3! Feast or famine.
0 · Reply
H177
H177 May. 13 at 9:51 PM
0 · Reply
4Realz
4Realz May. 12 at 1:30 PM
$CELZ 🤣
0 · Reply
H177
H177 May. 11 at 1:54 PM
0 · Reply
Kjstock
Kjstock May. 10 at 3:48 AM
$CELZ I don’t have time to run through it but they dropped the latest 10Q https://www.sec.gov/Archives/edgar/data/1187953/000147793226002893/celz_10q.htm
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb May. 8 at 1:48 PM
$CELZ 4+ when they give spine update?
1 · Reply
Latest News on CELZ
Creative Medical achieves second WHO INN milestone

2026-02-10T14:06:26.000Z - 3 months ago

Creative Medical achieves second WHO INN milestone


Creative Medical launches Biodefense Inc. Veterans Initiative

2025-10-30T13:20:14.000Z - 7 months ago

Creative Medical launches Biodefense Inc. Veterans Initiative


Creative Medical issues letter to shareholders

2025-10-27T12:30:51.000Z - 7 months ago

Creative Medical issues letter to shareholders


Creative Medical receives notice of allowance for ImmCelz

2025-07-11T12:10:13.000Z - 11 months ago

Creative Medical receives notice of allowance for ImmCelz


Creative Medical Technology Holdings Provides Corporate Update

Jul 10, 2024, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Provides Corporate Update


Kjstock
Kjstock May. 15 at 12:09 AM
$CELZ I wish that this was us! https://scitechdaily.com/scientists-reverse-stroke-damage-using-stem-cells-in-breakthrough-study/
1 · Reply
jcooptechit
jcooptechit May. 14 at 7:01 PM
$CELZ MAY BE NEARING A MAJOR BIOTECH INFLECTION POINT Creative Medical Technology is heading into a key May 2026 catalyst with top-line Phase 2 data expected for CELZ-201-DDT in chronic low-back pain linked to DDD. 🔸 Phase 2 clinical readout pending 🔸 Chronic pain / DDD = massive market 🔸 Multiple active Phase 2 programs 🔸 DSMB previously supported trial continuation 🔸 No Phase 3 results yet, so this is still early — but high-impact Strong data could quickly change the CELZ narrative and bring serious attention back to its regenerative medicine platform. This next update could be the spark. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $ABEO $ALLO $AUTL $CARM
0 · Reply
JTE_Theta
JTE_Theta May. 14 at 5:38 PM
Everyone's chasing AI stocks. Meanwhile $CELZ is quietly running one of the most interesting clinical pipelines in small cap biotech. Creative Medical Technology Holdings, $8.5M market cap. And a pipeline that punches way above its weight. Here's the story 🧵 79% of back pain patients hit meaningful improvements in pain & function. DSMB cleared. Zero safety flags. Then April 2026 - Ultrasome drops a 93% response rate in knee OA. Cell-free. Scalable. Whole new market unlocked. WHO has assigned INNs to TWO separate programs. Rare for any micro cap. Topline ADAPT data + T1 Diabetes readout both expected NOW. $20 B+ spinal market. FDA Fast Track. 60+ patents. Trading at $2.20 The market hasn't priced this in yet ommunicated Disclaimer:http://tinyurl.com/bdduhp5k
0 · Reply
jcooptechit
jcooptechit May. 14 at 2:42 PM
$CELZ COULD BE ONE CATALYST AWAY FROM A MAJOR MOMENTUM RE-RATE Creative Medical is tightening right as CELZ-201-DDT Phase 2 results for chronic low-back pain are expected in May 2026. Key levels on watch: * Accumulation: $1.70–$1.82 * Reaccumulation: $2.02–$2.20 * Breakout: $2.32 * Major Resistance: $2.72 🎯 Target Zone: $3.31–$3.68 The roadmap is simple: hold $2.02–$2.20, reclaim $2.32, attack $2.72, then eyes on $3.31+ With Phase 2 results potentially due any day now, volume confirmation could turn this setup from quiet accumulation into a serious catalyst-driven move. Keep CELZ locked in. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $VTGN $LCTX $ATHX.X $PSTV
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb May. 14 at 12:38 AM
$CELZ will find out soon if we're going to Phase 3! Feast or famine.
0 · Reply
H177
H177 May. 13 at 9:51 PM
0 · Reply
4Realz
4Realz May. 12 at 1:30 PM
$CELZ 🤣
0 · Reply
H177
H177 May. 11 at 1:54 PM
0 · Reply
Kjstock
Kjstock May. 10 at 3:48 AM
$CELZ I don’t have time to run through it but they dropped the latest 10Q https://www.sec.gov/Archives/edgar/data/1187953/000147793226002893/celz_10q.htm
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb May. 8 at 1:48 PM
$CELZ 4+ when they give spine update?
1 · Reply
H177
H177 May. 8 at 9:11 AM
$CELZ https://www.biodefenseinc.com/
0 · Reply
H177
H177 May. 7 at 8:14 PM
0 · Reply
Peterb3346
Peterb3346 May. 7 at 12:07 PM
$CELZ undervalued by a factor of at least 50x.
0 · Reply
H177
H177 May. 4 at 7:08 PM
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 4:03 PM
$CELZ : Momentum Building as Breakthrough Data Fuels Renewed Interest 🧬 Creative Medical Technology Holdings is gaining attention after its April 28 breakthrough, reporting a 93% response rate in its Ultrasome knee osteoarthritis program. Strong clinical results combined with improving price action are starting to bring momentum back to the story. Technical View: 🔸 Tight consolidation with buyers stepping in on dips 🔸 Higher lows forming, showing strength 🔸 Price compressing beneath resistance Key Levels to Watch: 📈 $2.02 🟰 Key support 📈 $2.21–$2.51 🟰 Current consolidation range 📈 $2.74 🟰 Breakout level 📈 $3.08–$3.34 🟰 Major resistance zone 📈 $3.86 🟰 High timeframe resistance With strong clinical momentum and multiple catalysts ahead, CELZ is targeting $100B+ markets, positioning itself for increased attention as the story continues to unfold. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $CYCN $DYAI $MBRX $AIXC
1 · Reply
jcooptechit
jcooptechit May. 4 at 4:03 PM
$CELZ SMART MONEY HEAT MAP IS FLASHING BULLISH CELZ is starting to look like a chart where the base has been built, the trend has shifted, and buyers are quietly stepping back in. The major level to watch is $2.50. A clean breakout above $2.50 could unlock momentum expansion and put $3.31 major resistance directly in play. Key Levels: 🔸Support/Accumulation: $1.70–$1.82 🔸 Reaccumulation: $2.15–$2.32 🔸 Breakout Trigger: $2.50 🔸 Major Resistance: $3.31 🔸 Target Zone: $3.68–$4.21 With the downtrend broken, higher lows forming, and CELZ building inside an ascending channel, the chart is showing signs that bulls may be gaining control. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 1:46 PM
$CELZ : A Microcap Biotech Targeting Massive Markets 🧬 Creative Medical Technology Holdings is a regenerative biotech developing stem cell therapies for chronic pain, diabetes, and immune conditions. 🔥 April 28 Breakthrough ✔️ Reported 93% response rate in Ultrasome knee OA study ✔️ Improved pain and mobility, no serious adverse events ✔️ Derived from CELZ-201, enabling a scalable cell free platform Recent Milestones ✔️ Completed enrollment in Phase 2 ADAPT trial ✔️ Positive interim data with strong response rates ✔️ Second WHO INN milestone, dual programs recognized Catalysts to Watch 🗓️ Full Phase 2 ADAPT data readout expected in 2026 🗓️ Expansion of Ultrasome into larger clinical studies 🗓️ Potential partnership or licensing discussions CELZ is expanding into a broader regenerative platform targeting osteoarthritis, chronic pain, and diabetes, a $100B+ opportunity. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $VXRT $HOOK $ATOS
0 · Reply
jcooptechit
jcooptechit May. 4 at 1:43 PM
🚨 93% RESPONSE RATE… AND $CELZ IS STILL UNDER THE RADAR 🧬 Ultrasome (derived from CELZ-201): ▪️ 93% response rate (pain + mobility) ▪️ ZERO serious adverse events ▪️ Cell-free, off-the-shelf = scalable 💡 This is the shift: Cell therapy ➝ mass-producible biologics 📊 THE SETUP ➝ Support: $1.20–$1.40 ➝ Resistance: $1.75–$1.90 ➝ Breakout: $2.00+ ➝ Targets: $2.50/ $3.00/ $4.00+ 📅 CATALYSTS ▪️ More clinical data ▪️ ADAPT trial updates ▪️ Partnerships / commercialization ⚠️ Multi-billion market + scalable model + strong data… CELZ feels like early-stage price discovery Watch this level closely 📣 Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $CAPR $AUTL $BMY
0 · Reply
BullTradeFinder
BullTradeFinder May. 4 at 1:37 PM
$CELZ Holding well, We need it to reclaim $2.30 for continued upside and get out of this chop range. Communicated-Disclaimer https://docs.google.com/document/d/1fwjSL77bbeirbtkV9xhygMAw1KQQyDa_h3Qw5uUSVeA/edit?usp=sharing
0 · Reply
H177
H177 May. 3 at 11:07 PM
0 · Reply
uppons
uppons May. 1 at 4:10 PM
0 · Reply
wokazn
wokazn May. 1 at 3:30 PM
$CELZ Ultrasome could be an IPSC, gene edited treatment, here is the patent application on it. https://www.patents-review.com/a/20250075185-orthopedic-regeneration-inducible-pluripotent-stem-cell.html
1 · Reply